Research identifies predictor of outcomes, chemoresistance for ovarian cancer patients | MDLinx
Published February 28, 2024 | Originally published on MedicalXpress Breakin g News-and-Events Key points summarized by the MDLinx Team. Newly published research from an international consortium led by the University of Minnesota’s Masonic Cancer Center has the potential to transform the landscape of ovarian cancer treatment. Published in JAMA Network Open, the findings indicate that ovarian cancer patients with high levels of stroma within their tumors are twice as likely to exhibit chemoresistance to